I2 therapeutics: strategy development for a disruptive cancer drug improvement biotech startup

Abstract

Cancer is a leading cause of death worldwide. Despite Big Pharma companies spending high amounts of resources on Research and Development of new drugs, their effectiveness leaves much to be desired. Our biotech startup ”I2 Therapeutics” addresses this gap in the market with a novel science-based solution called Syderum. Syderum is a system for targeted drug delivery to cancer cells while sparing healthy tissue. Thus, harmful side effects of chemotherapy can be alleviated, and patients’ lives can be improved. The scope of this project was to build a company and utilize entrepreneurial and science-based methods to establish and verify a novel business model. The result is a Business-to-Business (B2B) based model that focusses on the improvement of blockbuster chemotherapy drugs through co-development with leading companies in the pharmaceutical industry. Combining theory with entrepreneurial practice, a strategy for our company was developed that is ready to be fully executed.